dr subbiah on outcomes with larotrectinib in trk fusion–positive solid tumors
Published 3 weeks ago • 32 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:20
updated data with larotrectinib in trk fusion-positive solid tumors
-
1:15
larotrectinib, a trk inhibitor for patients with solid tumors
-
7:14
larotrectinib for solid tumors with ntrk gene fusions
-
1:14
dr. subbiah on safety and efficacy of blu-667 in ret-altered solid tumors
-
3:20
approaching treatment for trk fusion–positive cancers
-
3:18
larotrectinib in adult and pediatric patients with trk fusion-positive primary cns tumors
-
4:36
trk inhibition: personal experience with larotrectinib
-
6:51
entrectinib as treatment for ntrk-positive solid tumors
-
0:52
dr. van tilburg on larotrectinib in trk pediatric cancers
-
4:02
larotrectinib for patients with trk fusion-positive cns tumors
-
6:00
efficacy of trk inhibitors
-
4:41
trk inhibitors for solid tumors: overview
-
6:04
arrow: clinical activity of pralsetinib in ret-fusion positive solid tumors
-
5:08
larotrectinib for ntrk fusions: patient selection
-
1:13
larotrectinib in patients with trk fusion salivary gland tumours
-
0:39
larotrectinib is well-tolerated in metastatic solid tumors
-
2:53
other approaches to trk-fusion cancers
-
2:33
advocating for early ngs testing to identify trk fusion